Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9HAC7

UPID:
SUCHY_HUMAN

ALTERNATIVE NAMES:
Dermal papilla-derived protein 13; SuccinylCoA:glutarate-CoA transferase

ALTERNATIVE UPACC:
Q9HAC7; A4D1W5; B4DR73; Q4KMW4; Q4KMW8; Q4KMZ0; Q8TE00; Q8TEY1

BACKGROUND:
The enzyme Succinate--hydroxymethylglutarate CoA-transferase, alternatively known as SuccinylCoA:glutarate-CoA transferase, is pivotal in the metabolism of dicarboxylic acids. It efficiently catalyzes the conversion of glutarate to glutaryl-CoA, with a preference for specific substrates such as glutarate and succinate.

THERAPEUTIC SIGNIFICANCE:
Associated with Glutaric aciduria 3, a disorder characterized by abnormal glutaric acid excretion, the enzyme's dysfunction highlights its potential as a target for therapeutic intervention. Exploring the enzyme's role could lead to novel treatments for this metabolic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.